Objective: Evaluate blood mitochondrial DNA (mtDNA) content in HIV/antiretroviralexposed uninfected (HEU) vs. HIV-unexposed uninfected (HUU) infants and investigate differences in mitochondrial-related metabolites by exposure group.
Introduction
In 1999, one of the first reports of clinical mitochondrial dysfunction in infants exposed to HIV and nucleoside reverse transcriptase inhibitors (NRTIs) emerged, demonstrating neurological impairment in these infants [1] . Since then, concern has evolved regarding the short-term and long-term effects of in-utero antiretrovirals on the developing fetus. Several studies have shown abnormalities in mitochondrial DNA (mtDNA) content [2] [3] [4] [5] [6] [7] [8] , aberrant mitochondrial morphology [1, 3] , respiratory chain compromise [8, 9] , and also significant mitochondriopathy presenting as seizures, cognitive delays, motor and cardiac dysfunction, and even death [1, 10] .
Definitive assessment of mitochondrial dysfunction is difficult and requires direct measurement of mitochondrial respiration which is not always feasible. Therefore, several studies have evaluated other aspects of mitochondria such as mitochondrial histology [1, 3] , DNA content [2] [3] [4] [5] , and oxidative phosphorylation (OXPHOS) enzyme activity [8, 9] . Another aspect of mitochondrial health includes the biochemical reactions which produce cellular metabolites or energy and localize to the mitochondria such as fatty acid (FA) oxidation, glycolysis, and parts of amino-acid catabolism. Intermediary metabolites involved in these metabolic pathways include, but are not limited to, acylcarnitines and amino acids, the latter of which includes branched-chain amino acids (BCAAs). Studies have demonstrated that HIV/antiretroviral-exposed uninfected (HEU) infants exhibit higher rates of abnormal acylcarnitine profiles than the general population [11, 12] . Moreover, we have also previously described a signature array of short-chain acylcarnitines and BCAAs in association with insulin resistance in HEU infants [13] . Few studies have evaluated mtDNA content or the relationship between mtDNA levels and pathways of intermediary metabolism in HEU compared with HIV-unexposed uninfected (HUU) infants in Africa.
Given that approximately 20% of the general pediatric population is currently HEU in sub-Saharan Africa [14] , we sought to assess mtDNA content in HEU infants in Cameroon and investigate its relationship with intermediary metabolites.
Materials and methods

Study population
Between 2011 and 2014, HIV-infected and HIVuninfected pregnant woman/infant pairs were enrolled at the Nkwen Family Care and Treatment Center, within the Cameroon Baptist Convention Health Services (CBCHS) consortium. This was a prospective cohort study where pregnant women were enrolled between 20 and 36-week gestation and followed through delivery until the infant reached 12 months of age. Blood specimens were collected on infants at 6 weeks of life, and subsequent study visits occurred at 6 and 12 months after delivery. The design of this study has been previously reported [13] . Multiple gestation pregnancies and those ending in spontaneous/therapeutic abortions or intrauterine fetal demise, as well as infants with HIV infection by positive DNA PCR testing at 6 weeks of life were excluded. During the study period, national guidelines for the Prevention of Mother-To-Child Transmission (PMTCT) of HIV underwent changes, reflecting updated WHO Guidelines [15, 16] . At study initiation, national PMTCT guidelines recommended that HIV-infected pregnant women with a CD4 þ cell count 350 cells/ml or less or WHO Stage III/IV disease be eligible for lifetime combination antiretroviral therapy (ART), while their infants received nevirapine for 4-6 weeks after birth. Pregnant women with a CD4 þ cell count more than 350 cells/ml received prenatal zidovudine monotherapy and single-dose nevirapine intrapartum and nevirapine/ lamivudine for 1-week postpartum; infant nevirapine prophylaxis was administered until cessation of breastfeeding as women with higher CD4 þ cell counts were not receiving ART during breastfeeding. During the final year of the study, national guidelines expanded PMTCT services extending lifetime ART eligibility to all HIVinfected pregnant women, regardless of maternal CD4 þ cell count, and HIV-exposed infants received prophylactic nevirapine for 6 weeks. First-line ART for pregnant women in Cameroon during the time of the study consisted of zidovudine/lamivudine/nevirapine. In addition, during the study, there were random periods where infant nevirapine shortages occurred throughout the country, and thus zidovudine was administered as infant prophylaxis instead of nevirapine as per national protocols. Because of this, we were able to evaluate and compare a sample population of HEU infants exposed with infant nevirapine vs. zidovudine prophylaxis. All infants in this study were breast-fed. Informed consent was provided by all women for their and their infants' participation, and this study was approved by the Institutional Review Boards of CBCHS and the Icahn School of Medicine at Mount Sinai.
Primary outcome
We measured mtDNA content in dried blood spot (DBS) collected at 6 weeks of life in HEU and HUU infants. DBS specimens were collected via heel stick method, dried appropriately, then shipped at 0 8C and stored at À80 8C until the time of biochemical assessments. DBS DNA was extracted from six 3-mm discs using the QIAamp DNA Mini Kit on the QIAcube (QIAGEN, Hilden, Germany), using a customized DBS protocol. The extraction yielded 50 ml at typically 2-6 ng/ml. The mtDNA content, expressed as the ratio between mtDNA copy number (D loop region) and the copy number of a single-copy nuclear gene (albumin), was determined using a monochrome multiplex quantitative PCR, adapted from a published assay for relative telomere length [17] . DNA extracts were assayed on the LightCycler 480 Roche Diagnostics Ltd., Rotkreuz, Switzerland). For each reaction, 2 ml of DNA was added to 8 ml of master mix for final concentrations of 1X FastStart SYBR Green Master (Roche), 1.2 mmol/l ethylenediaminetetraacetic acid, and 0.9 mmol/l for each of the four primers (refer to Supplemental Tables 1 and 2 , http://links.lww.com/QAD/B166 for primer sequences and thermal-cycling profile). Each extract was assayed in duplicate, and each plate included a standard curve generated by 1 : 5 serial dilution of two cloned plasmids (one containing the albumin the other the D-loop amplicon, and mixed in a 1 : 50 albumin : Dloop ratio), as well as two internal controls. The assay's intra-assay and interassay coefficients of variation were 5 and 8%, respectively.
Primary exposure of interest
The primary exposure of interest was in-utero/postnatal antiretrovirals. Per maternal serological HIV ELISA testing, infant HIV DNA PCR testing at 6-weeks of life, and ART history, infants were categorized as, inutero HIV/antiretroviral and postnatal zidovudineexposed, uninfected (HEU-Z); in-utero HIV/antiretroviral and postnatal nevirapine-exposed, uninfected (HEU-N); and HIV/antiretroviral-unexposed uninfected (HUU). Maternal ART history was assessed via self-report as well as medical and pharmacy record review. Infants were considered exposed to postnatal zidovudine if they received at least 4 weeks of zidovudine or exposed to postnatal nevirapine if they received at least 4 weeks of nevirapine after birth, prior to insulin assessment at 6 weeks of life.
Covariates Information on maternal sociodemographics, obstetrical history, and HIV immune status as well as infant birth outcomes and anthropometrics was collected. Infant weight, length, and head circumference were measured in standardized fashion using a recumbent stadiometer, manual scale, and paper tape measures, respectively, by one of two trained research assistants.
Biochemical measurements
Using an Agilent 6460 tandem mass spectrometry coupled with an Agilent 1260 liquid chromatography system, we measured 37 acylcarnitines and three BCAAs (leucine, isoleucine, and valine) from stored DBS specimens which had been collected from infants at 6 weeks of life. Acylcarnitines and BCAAs were extracted with methanol containing stable isotope internal standards of acylcarnitines and BCAAs. Dried acylcarnitine and BCAA extracts were derivatized with 3 N-butanolic HCl to form their respective butyl esters. Butyl esters of acylcarnitines were analyzed in the positive ion mode using a flow injection program and selective reaction monitoring (SRM) [18] . Butyl esters of BCAAs were separated on Zorbax Eclipse Plus C8 column and analyzed in the positive ion mode and SRM.
Statistical analysis
Characteristics of pregnant women and their infants were compared between groups using Kruskal-Wallis or analysis of variance tests as appropriate. Weight-forage, length-for-age, weight-for-length, and head circumference-for-age z-scores were calculated from WHO 2006 child growth standards [19] . The ratio of mtDNA : -nuclear DNA was three-quarter-root transformed using the Box Cox transformation to normalize the variable. Principal component analysis (PCA) using an orthogonal rotation was performed as a means of reducing the number of acylcarnitine and BCAA metabolite variables, converting the 40 possibly correlated metabolites into a set of values of uncorrelated variables defined as principal components. The number of components was chosen based on eigenvalues more than 1, scree plots, and theoretical congruence with prior knowledge of intermediate metabolic pathways as previously described [13] . Principal component scores were calculated for each infant as a linear combination of the optimally weighted metabolites (based on standardized scoring coefficients) with each principal component score representing the level of activity for a particular mitochondrial metabolic pathway [13] . Correlations between each of the principal components and mtDNA ratio were evaluated using Spearman's correlation. Lastly, linear regression modeling was applied to assess the association of in-utero HIV/ antiretroviral and either postnatal zidovudine or nevirapine with mtDNA content while adjusting for confounders and PCA-derived principal component scores of the metabolites. All principal components were forced into the final model to fully adjust for and evaluate any residual confounding effects of intermediary metabolites on mtDNA content. In addition, we tested for interactions between infant in-utero HIV/antiretroviral and postnatal antiretroviral exposure, and each principal component score on the primary outcome. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina, USA).
Results
A total of 364 singleton infants were included in this analysis: 38 were HEU-Z, 117 HEU-N, and 209 HUU infants. Mothers of HEU-Z and HEU-N were older than those of HUU infants (median age 30 vs. 30 vs. 28 years, respectively, P 0.01) and less likely to have completed a high school education or higher (32 vs. 34 vs. 48%, respectively, P ¼ 0.023) ( Table 1) . Among HEU infants, 15 (10%) were not exposed to any in-utero antiretrovirals, 33 (21%) to in-utero zidovudine monotherapy, and 108 (69%) to combination ART. Of those exposed to combination ART, only two were exposed to lopinavir/ritonavir, whereas the remainder were exposed to a non-NRTI (NNRTI)-based regimen. The types of in-utero antiretroviral exposures did not differ significantly between HEU-Z and HEU-N infants.
As previously described [13] , we used PCA to consolidate and reduce the total number of acylcarnitine and BCAA metabolites into a smaller number of uncorrelated variables/components. In general, principal component 1 comprised long-chain acylcarnitines and free carnitine (C0), principal component 2 of 3-hydroxy long-chain acylcarnitines, principal component 3 of short-chain and BCAA-related acylcarnitines, principal component 4 of unsaturated medium-chain and long-chain acylcarnitines, principal component 5 of BCAAs, principal component 6 of adipoyl/3-methylglutarylcarnitine (C6-DC) and dodecanoylcarnitine (C12) acylcarnitines, and principal component 7 of medium-chain acylcarnitines and tetradecenoylcarnitine (C14 : 1) (Supplemental Table 3 , http://links.lww.com/QAD/B166).
Overall, mtDNA ratio at 6 weeks of life was lowest in HEU-Z followed by HEU-N and highest in HUU infants (140 vs. 160 vs. 174, overall P ¼ 0.004; for HEU-Z vs. HUU infants, P ¼ 0.001) (Fig. 1) . This difference remained statistically significant when comparing the mtDNA ratio between HEU-Z and HEU-N infants (P ¼ 0.048) but not when comparing HEU-N and HUU infants. Principal component 3 (short-chain and BCAArelated acylcarnitines) and mtDNA ratio were positively associated (rho ¼ 0.3, P < 0.001) (Fig. 2) . No correlation was found between the other principal components and mtDNA ratio in univariate analyses. After adjustment for potential confounders, in-utero HIV/antiretroviral and 2478 AIDS 2017, Vol 31 No 18 postnatal zidovudine exposure remained associated with a lower mtDNA ratio at 6 weeks of life (b ¼ À4.46, P ¼ 0.045 for HEU-Z vs. HUU and b ¼ À1.68, P ¼ 0.269 for HEU-N vs. HUU infants) ( Table 2 ). In addition, long-chain acylcarnitines and C0 (principal component 1) were associated with a decreased mtDNA ratio (b ¼ À2.35, P ¼ 0.002), whereas short-chain and BCAA-related acylcarnitines were associated with an increased mtDNA ratio (b ¼ 2.96, P ¼ 0.001) (Fig. 2) .
Discussion
In this cohort of HEU and HUU infants in Cameroon, we found that in-utero HIV/antiretroviral exposure and postnatal zidovudine was associated with decreased mtDNA content at 6 weeks of life. In addition, lower mtDNA content in HEU-Z infants may be associated with altered mitochondrial fuel utilization.
Despite conflicting results in the literature on mtDNA content in HEU infants [2] [3] [4] [5] [6] [7] [8] , our results are consistent with other reports comparing HEU with HUU infants. The Women and Infants Transmission Study (WITS) reported lower mtDNA content in cord blood mononuclear cells (CBMCs) and infant peripheral blood mononuclear cells (PBMCs) of HEU infants exposed in utero to zidovudine compared with HUU infants [2] , whereas another US study reported similar findings in HEU infants exposed in utero to zidovudine/lamivudine compared with HUU infants [3] . In a large combined analysis of WITS and the Pediatric AIDS Clinical Trials Group 1009 Protocol, significantly lower mtDNA was observed in HEU vs. HUU infants at birth and 2 years of life with the following in-utero exposures demonstrating higher mtDNA levels in increasing order: in-utero HIV, but no antiretroviral exposure less than in-utero HIV and zidovudine monotherapy exposure less than in-utero HIV and zidovudine/lamivudine exposure less than HUU infants [4] . Of note, in our cohort, we also observed lower mtDNA levels among HEU infants with in-utero HIV, but no antiretroviral exposure compared with those with in-utero HIV and zidovudine monotherapy exposure (140 vs. 163, data not shown), but were limited by a small number (n ¼ 15) of HEU infants who
Mitochondrial DNA in HIV-exposed infants Jao et al. had no in-utero antiretroviral exposures. One small Tanzanian study found similar results showing lower mtDNA levels at birth in CBMCs between infants with in-utero HIV, but no antiretroviral exposure vs. in-utero HIV and zidovudine monotherapy exposure. However, this study lacked an HUU comparison group [7] .
In contrast, three North American studies have demonstrated higher mtDNA content in HEU compared with HUU infants [5, 6, 8] . Two were US studies which evaluated mtDNA content from infant PBMCs [6, 8] , whereas the other evaluated mtDNA levels in whole blood [5] . In the North American studies, the majority of participants were exposed to protease inhibitors, unlike our study where all but two HEU infants were exposed in utero to combination NNRTIs ART. In-vitro studies have shown that protease inhibitors may potentially increase mtDNA levels [20] . The fact that we observed lower and not higher mtDNA content in our cohort may also be explained by possible racial or ethnic differences. Our participants were all black African, whereas North American studies often report imbalance between the ethnic make-up of the HUU and HEU groups. It is also important to note that differences in whole blood, PBMC, or CBMC testing may account for some differences in reported results. Lastly, all studies to date have had HEU infants with the same infant prophylaxis, namely zidovudine for the first 4-6 weeks of life. Our study is one of the first to attempt to compare mtDNA content based on infant prophylaxis regimens during the first 6 weeks of life.
In addition to assessing mtDNA content level, we sought to better understand whether lower mtDNA content reflected abnormal mitochondrial fuel utilization. mtDNA polymerase-? is required for mtDNA replication and has been shown to be inhibited by dideoxy analog antiretrovirals such as zidovudine, stavudine, and didanosine [21] . In studies of mtDNA polymerase-?-related disorders, mtDNA depletion has been shown to result in OXPHOS dysfunction and respiratory chain compromise of the mitochondria [22] . A reduction in OXPHOS may presumably cause perturbations in FA oxidation within the mitochondria [23, 24] . As a result, inefficient FA oxidation from decreased mtDNA and mitochondrial dysfunction could manifest by increased levels of longchain acylcarnitines due to substrate back-up, which here we see reflected in the negative association between principal component 1 and mtDNA in multivariate analysis. Acylcarnitine levels increase, in general, when fuel utilization does not equal fuel supply. The positive association between principal component 3 and mtDNA seen reflects the decreased levels of short-chain acylcarnitines and BCAA-related acylcarnitines seen when mtDNA is decreased, a situation indicating ineffective FA and BCAA oxidation. Both scenarios were observed in our study. Though it is difficult to determine direct causal pathways between decreased mtDNA content and definitive flux of intermediary metabolites, we have demonstrated that decreased mtDNA content in HEU-Z infants appears to be linked to abnormal fuel utilization in the mitochondria, the long-term significance of which is unclear. Given that a substantial proportion of the pediatric population in sub-Saharan Africa is currently born HEU, it will be important to monitor the mitochondrial and metabolic health of this potentially vulnerable population for long-term effects of decreased mtDNA content and potential metabolic sequelae.
Our study is limited by the lack of longitudinal data on mtDNA content, restricting our ability to draw inferences about the long-term consequences of our findings in early infancy. In addition, we were not able to directly assess mitochondrial function. Lastly, because of the observational nature of our study design, we were not able to disentangle the effects of in-utero antiretroviral exposure from postnatal antiretroviral exposure. However, no differences were observed in the types of in-utero antiretroviral exposure between HEU-Z and HEU-N infants.
In conclusion, compared with HUU infants, HEU infants in Cameroon receiving postnatal zidovudine prophylaxis appear to be at increased risk for decreased blood mtDNA content. Moreover, in our cohort, decreased mtDNA content in HEU-Z infants was associated with altered mitochondrial fuel utilization. Further studies are needed to assess the long-term significance of these findings. 
